Media headlines about Halyard Health (NYSE:HYH) have been trending somewhat positive recently, Accern reports. The research firm ranks the sentiment of media coverage by analyzing more than 20 million blog and news sources in real time. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores closest to one being the most favorable. Halyard Health earned a news sentiment score of 0.18 on Accern’s scale. Accern also assigned headlines about the medical instruments supplier an impact score of 45.7793358452013 out of 100, meaning that recent media coverage is somewhat unlikely to have an impact on the stock’s share price in the immediate future.
Halyard Health (NYSE:HYH) opened at 45.30 on Friday. The stock’s 50 day moving average price is $43.40 and its 200-day moving average price is $39.60. The company has a market cap of $2.12 billion, a PE ratio of 43.56 and a beta of 1.76. Halyard Health has a 1-year low of $31.59 and a 1-year high of $46.36.
Halyard Health (NYSE:HYH) last released its quarterly earnings results on Wednesday, August 2nd. The medical instruments supplier reported $0.51 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $0.37 by $0.14. The firm had revenue of $399.20 million for the quarter, compared to analyst estimates of $399.16 million. Halyard Health had a net margin of 3.06% and a return on equity of 8.29%. The business’s revenue for the quarter was down .2% compared to the same quarter last year. During the same quarter in the previous year, the company earned $0.45 EPS. On average, analysts forecast that Halyard Health will post $1.98 earnings per share for the current year.
Several brokerages have weighed in on HYH. BidaskClub cut Halyard Health from a “buy” rating to a “hold” rating in a research note on Saturday, July 8th. TheStreet raised Halyard Health from a “c” rating to a “b” rating in a research note on Thursday, June 22nd. Zacks Investment Research raised Halyard Health from a “hold” rating to a “buy” rating and set a $44.00 price objective on the stock in a research note on Wednesday, July 12th. Stephens raised Halyard Health from an “equal weight” rating to an “overweight” rating in a research note on Thursday, August 3rd. Finally, Deutsche Bank AG boosted their price objective on Halyard Health from $35.00 to $42.00 and gave the stock a “buy” rating in a research note on Thursday, August 3rd. One equities research analyst has rated the stock with a hold rating and five have given a buy rating to the company. The stock currently has an average rating of “Buy” and an average price target of $42.25.
Halyard Health Company Profile
Halyard Health, Inc is a medical technology company. The Company operates through two segments: Medical Devices and Surgical and Infection Prevention (S&IP). The Medical Devices segment provides a portfolio of product offerings focused on pain management, respiratory and digestive health. The S&IP segment provides healthcare supplies and solutions that target the prevention of healthcare-associated infections.
Receive News & Ratings for Halyard Health Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Halyard Health Inc. and related companies with MarketBeat.com's FREE daily email newsletter.